GB9603507D0 - Antibody variants - Google Patents

Antibody variants

Info

Publication number
GB9603507D0
GB9603507D0 GBGB9603507.6A GB9603507A GB9603507D0 GB 9603507 D0 GB9603507 D0 GB 9603507D0 GB 9603507 A GB9603507 A GB 9603507A GB 9603507 D0 GB9603507 D0 GB 9603507D0
Authority
GB
United Kingdom
Prior art keywords
antibody
therapeutic antibody
therapeutic
antigen
antibody variants
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GBGB9603507.6A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford University Innovation Ltd
Original Assignee
Oxford University Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford University Innovation Ltd filed Critical Oxford University Innovation Ltd
Priority to GBGB9603507.6A priority Critical patent/GB9603507D0/en
Publication of GB9603507D0 publication Critical patent/GB9603507D0/en
Priority to NZ331299A priority patent/NZ331299A/xx
Priority to CA002246715A priority patent/CA2246715C/en
Priority to DE69738138T priority patent/DE69738138T2/de
Priority to US09/125,460 priority patent/US20020048578A1/en
Priority to JP52989397A priority patent/JP4574750B2/ja
Priority to EP97905226A priority patent/EP0970127B1/en
Priority to AU18851/97A priority patent/AU723366B2/en
Priority to PCT/GB1997/000472 priority patent/WO1997031024A1/en
Priority to AT97905226T priority patent/ATE373016T1/de
Priority to ES97905226T priority patent/ES2294793T3/es
Priority to US11/180,631 priority patent/US8440190B2/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
GBGB9603507.6A 1996-02-20 1996-02-20 Antibody variants Pending GB9603507D0 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
GBGB9603507.6A GB9603507D0 (en) 1996-02-20 1996-02-20 Antibody variants
ES97905226T ES2294793T3 (es) 1996-02-20 1997-02-20 Induccion de tolerancia inmunologica a un anticuerpo terapeutico usando variantes de dicho anticuerpo terapeutico.
US09/125,460 US20020048578A1 (en) 1996-02-20 1997-02-20 Antibody variants
CA002246715A CA2246715C (en) 1996-02-20 1997-02-20 Antibody variants
DE69738138T DE69738138T2 (de) 1996-02-20 1997-02-20 Induktion von immunologischer Toleranz gegen einen therapeutischen Antikörper durch Varianten des therapeutischen Antikörpers
NZ331299A NZ331299A (en) 1996-02-20 1997-02-20 Antibody variants with reduced affinity for a cell-surface antigen
JP52989397A JP4574750B2 (ja) 1996-02-20 1997-02-20 抗体変異物
EP97905226A EP0970127B1 (en) 1996-02-20 1997-02-20 Induction of immunological tolerance to a therapeutic antibody using variants of the said therapeutic antibody
AU18851/97A AU723366B2 (en) 1996-02-20 1997-02-20 Antibody variants
PCT/GB1997/000472 WO1997031024A1 (en) 1996-02-20 1997-02-20 Antibody variants
AT97905226T ATE373016T1 (de) 1996-02-20 1997-02-20 Induktion von immunologischer toleranz gegen einen therapeutischen antikörper durch varianten des therapeutischen antikörpers
US11/180,631 US8440190B2 (en) 1996-02-20 2005-07-14 Antibody variants

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9603507.6A GB9603507D0 (en) 1996-02-20 1996-02-20 Antibody variants

Publications (1)

Publication Number Publication Date
GB9603507D0 true GB9603507D0 (en) 1996-04-17

Family

ID=10789047

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9603507.6A Pending GB9603507D0 (en) 1996-02-20 1996-02-20 Antibody variants

Country Status (11)

Country Link
US (2) US20020048578A1 (enExample)
EP (1) EP0970127B1 (enExample)
JP (1) JP4574750B2 (enExample)
AT (1) ATE373016T1 (enExample)
AU (1) AU723366B2 (enExample)
CA (1) CA2246715C (enExample)
DE (1) DE69738138T2 (enExample)
ES (1) ES2294793T3 (enExample)
GB (1) GB9603507D0 (enExample)
NZ (1) NZ331299A (enExample)
WO (1) WO1997031024A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2229043C (en) * 1995-08-18 2016-06-07 Morphosys Gesellschaft Fur Proteinoptimierung Mbh Protein/(poly)peptide libraries
US6037454A (en) 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
JP2002530081A (ja) 1998-11-18 2002-09-17 ジェネンテック・インコーポレーテッド 親抗体より高度な結合親和性を持つ抗体変異体
AU9399501A (en) * 2000-10-09 2002-04-22 Isis Innovation Therapeutic antibodies
US7465790B2 (en) 2000-10-09 2008-12-16 Isis Innovation, Inc. Therapeutic antibodies
US20040109855A1 (en) * 2002-07-23 2004-06-10 Herman Waldmann Therapeutic antibodies with reduced side effect
JPWO2004087210A1 (ja) * 2003-03-31 2006-06-29 麒麟麦酒株式会社 抗ｃｄ５２抗体による調節性ｔ細胞分化誘導・増殖方法およびそのための医薬組成物
WO2005114215A2 (en) * 2004-05-19 2005-12-01 Avidex Ltd Method of improving t cell receptors
WO2006100449A1 (en) * 2005-03-19 2006-09-28 Medical Research Council Improvements in or relating to treatment and prevention of viral infections
PE20070207A1 (es) * 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
US20100197896A1 (en) * 2007-05-16 2010-08-05 Leung Shui-On Functional humanization of complementarity determining regions (cdrs)
EP3492488A1 (en) 2007-08-22 2019-06-05 The Regents of The University of California Activatable binding polypeptides and methods of identification and use thereof
WO2010081173A2 (en) 2009-01-12 2010-07-15 Cytomx Therapeutics, Llc Modified antibody compositions, methods of making and using thereof
AU2010215761B2 (en) * 2009-02-23 2017-04-06 Cytomx Therapeutics, Inc Proproteins and methods of use thereof
KR20160005143A (ko) 2009-05-13 2016-01-13 젠자임 코포레이션 항-인간 ｃｄ52 면역글루불린
NZ596603A (en) 2009-05-29 2013-07-26 Morphosys Ag A collection of antibodies or fragments having properties relevant to developability
DK2640742T3 (en) 2010-11-19 2018-12-03 Morphosys Ag COLLECTION OF ANTIBODY SEQUENCES AND THEIR APPLICATIONS
GB201109238D0 (en) * 2011-06-01 2011-07-13 Antitope Ltd Antibodies
US9494597B2 (en) * 2012-04-02 2016-11-15 Ab Biosciences, Inc. Human control antibodies and uses therefor
AU2013251310B2 (en) 2012-04-27 2018-02-15 Cytomx Therapeutics, Inc. Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
JP6433085B2 (ja) 2013-04-09 2018-12-05 ボストン バイオメディカル， インコーポレイテッド がんの処置に使用するための２−アセチルナフト［２，３−ｂ］フラン−４，９−ジオン
US9540440B2 (en) 2013-10-30 2017-01-10 Cytomx Therapeutics, Inc. Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
US9737623B2 (en) 2013-12-11 2017-08-22 Cytomx Therapeutics, Inc. Antibodies that bind activatable antibodies and methods of use thereof
US20160120158A1 (en) * 2014-11-03 2016-05-05 The Johns Hopkins University Compositions and methods for the study and treatment of acute kidney injury
EA201792623A1 (ru) 2015-06-03 2018-04-30 Бостон Биомедикал, Инк. Композиции, содержащие ингибитор стволовости рака и иммунотерапевтический агент, для применения в лечении рака
US11299469B2 (en) 2016-11-29 2022-04-12 Sumitomo Dainippon Pharma Oncology, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
WO2018213424A1 (en) 2017-05-17 2018-11-22 Boston Biomedical, Inc. Methods for treating cancer
US12465637B2 (en) 2019-04-30 2025-11-11 Institute For Cancer Research Compositions and methods for modulation of antibody activity

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5846534A (en) 1988-02-12 1998-12-08 British Technology Group Limited Antibodies to the antigen campath-1
WO1989007452A1 (en) * 1988-02-12 1989-08-24 Medical Research Council Improvements in or relating to antibodies
US5858725A (en) 1990-10-10 1999-01-12 Glaxo Wellcome Inc. Preparation of chimaeric antibodies using the recombinant PCR strategy
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
EP0610447B1 (en) * 1991-10-15 1998-12-16 Btg International Limited CDw52 - SPECIFIC ANTIBODY FOR TREATMENT OF T-CELL MEDIATED INFLAMMATION OF THE JOINTS
GB9125768D0 (en) * 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method

Also Published As

Publication number Publication date
US20060018898A1 (en) 2006-01-26
EP0970127A1 (en) 2000-01-12
AU1885197A (en) 1997-09-10
NZ331299A (en) 2000-05-26
ES2294793T3 (es) 2008-04-01
AU723366B2 (en) 2000-08-24
DE69738138D1 (de) 2007-10-25
US20020048578A1 (en) 2002-04-25
WO1997031024A1 (en) 1997-08-28
JP4574750B2 (ja) 2010-11-04
DE69738138T2 (de) 2008-06-05
CA2246715C (en) 2008-08-05
JP2000506723A (ja) 2000-06-06
CA2246715A1 (en) 1997-08-28
ATE373016T1 (de) 2007-09-15
US8440190B2 (en) 2013-05-14
EP0970127B1 (en) 2007-09-12

Similar Documents

Publication Publication Date Title
GB9603507D0 (en) Antibody variants
AU4230493A (en) Diphtheria toxin receptor-binding region
HUT74845A (en) Antibody purification
AU3053395A (en) Immunoconjugates II
MX9603080A (es) Anticuerpos monoclonales inmuno-estimulantes.
WO1998026747A3 (en) Superantigen based methods and compositions for treatment of diseases
WO2003016467A3 (en) Use of antibodies having high affinity for soluble ass to treat conditions and diseases related to ass
EP0701571A1 (en) ANTIBODY FRAGMENTS IN THERAPY
PT1135498E (pt) Variantes de anticorpos com maior afinidade de ligação em comparação com os anticorpos parentais
NO883306D0 (no) Farmasoeytisk aktive konjugater med forbedret bindingsspesifisitet for kroppsvev.
ZA897858B (en) Family of high affinity,modified antibodies for cancer treatment
AU2967595A (en) Anti-protozoan methods and materials
EP1354599A3 (fr) Composition pharmaceutique ou alimentaire pour le traitement de pathologies liees a un rejet de greffe
AU6921300A (en) Novel glycoconjugates, glycoamino, acids, intermediates thereto, and uses thereof
EP0955366A4 (en) ANTIGENIC PROTEIN FROM MALASSEZIA
WO1991010735A3 (fr) Recepteur humain de la tsh. sequence codant pour ce recepteur
EP1039931A4 (en) MULTIVALENT RECOMBINANT ANTIBODIES FOR THE TREATMENT OF HUMAN RHINOVIRUS (HRV) INFECTIONS
AU653332B2 (en) Synthetic peptides which contain sequences from factor VIIa, and the use thereof
ATE309371T1 (de) Protein mit dnase-aktivität
DK0858465T3 (da) Protein med antitumorvirkning.
BR1100558A (pt) famìlia de anticorpos modificados, com elevada afinidade, para tratamento de cáncer.
AU6162794A (en) Carcinoma associated antigen (ng1) monoclonal antibodies against ng1, methods of producing these antibodies and use therefor
AU7000798A (en) Pharmaceutical antigen-antibody preparation
UA30268A (uk) Фітозасіб, стимулюючий антитілогенез
BR1100582B1 (pt) famÍlia de anticorpos modificados, de alta afinidade, para tratamento de cÂncer.